Title

Cabozantinib in combination with atezolizumab as a first-line therapy in patients with radioiodinerefractory differentiated thyroid cancer: Results from cohort 18 of the phase 1b COSMIC-21 study.

Authors

M Taylor, Providence

Document Type

Presentation

Publication Date

10-19-2022

Keywords

oregon; chiles

Clinical Institute

Cancer

Department

Oncology

Department

Earle A. Chiles Research Institute

Comments

Presented at the American Thyroid Association Conference 2022 October 19-23; Montreal, Quebec Canada.

Recommended Citation

Taylor, M, "Cabozantinib in combination with atezolizumab as a first-line therapy in patients with radioiodinerefractory differentiated thyroid cancer: Results from cohort 18 of the phase 1b COSMIC-21 study." (2022). Articles, Abstracts, and Reports. 6876.
https://digitalcommons.providence.org/publications/6876